Close Menu

Ohio State

The projects are focused on the impact of microbe communities on soil nutrient cycling, and the relationship between gene function and beneficial plant traits.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

In Genome Research this week: links between biological aging and mutations affecting epigenetic regulators; long-read sequencing-based strategy to map chromatin accessibility; and more.

In Cell this week: DNA-based survey of marine virus genomes,  single-cell atlas of tumor proteomic profiles, and more.

Suit for Chair

According to Retraction Watch, Ohio State University's Carlo Croce is suing to be reinstated as department chair.

Ohio State University researchers found that a phosphorothioate-modified DNA-crRNA duplex completely blocked the function of Cas12a.

A brief recap of Genetics/Genomics news the week of Dec 14, 2018: AstraZeneca, NeoGenomics, Fluidigm, Luminex, Petco Foundation, and SQI Diagnostics

Croce Out as Chair

Retraction Watch reports Ohio State has pushed Carlo Croce to step down as department chair.

Mostly Dismissed

Retraction Watch reports that a judge dismissed most of the lawsuit Ohio State University's Carlo Croce brought against the New York Times.

Patients whose tumors had methylated MGMT promoters were more likely to survive than those that did not after combination treatment with radiotherapy and temozolomide.

Pages

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.